[go: up one dir, main page]

CA2392369A1 - Traitement des troubles du rythme cardiaque au moyen de carboxamidoadenosines n6-substitutees-5'-(n-substitutees) - Google Patents

Traitement des troubles du rythme cardiaque au moyen de carboxamidoadenosines n6-substitutees-5'-(n-substitutees) Download PDF

Info

Publication number
CA2392369A1
CA2392369A1 CA002392369A CA2392369A CA2392369A1 CA 2392369 A1 CA2392369 A1 CA 2392369A1 CA 002392369 A CA002392369 A CA 002392369A CA 2392369 A CA2392369 A CA 2392369A CA 2392369 A1 CA2392369 A1 CA 2392369A1
Authority
CA
Canada
Prior art keywords
compound
cyclopentyl
carboxamidoadenosine
ethyl
cyclopropyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002392369A
Other languages
English (en)
Inventor
Pauline L. Martin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aderis Pharmaceuticals Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2392369A1 publication Critical patent/CA2392369A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

L'invention concerne une méthode permettant de traiter les troubles du rythme cardiaque chez un mammifère qui en a besoin en lui administrant des carboxamidoadénosines N?6¿-substitutées-5'-(N-substitutées). D'une manière plus spécifique, l'invention concerne une méthode permettant de traiter les troubles du rythme cardiaque chez un mammifère qui tirerait avantage de l'induction d'actions dromotropes négatives et/ou chronotropes négatives consistant à administrer à ce mammifère un quantité efficace d'un composé représenté par la formule (I) ou un sel ou ester pharmaceutiquement acceptable de ce composé. Dans cette formule R¿1? représente un alkyle secondaire C¿3-7? ou un cycloalkyle C¿3-8?; et R¿2? représente un alkyle C¿1-4? ou un cycloalkyle C¿3-5?. L'invention concerne également de nouvelle formes posologiques contenant ces composés.
CA002392369A 1999-11-23 2000-11-16 Traitement des troubles du rythme cardiaque au moyen de carboxamidoadenosines n6-substitutees-5'-(n-substitutees) Abandoned CA2392369A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16701499P 1999-11-23 1999-11-23
US60/167,014 1999-11-23
PCT/US2000/031417 WO2001037845A1 (fr) 1999-11-23 2000-11-16 Traitement des troubles du rythme cardiaque au moyen de carboxamidoadenosines n6-substitutees-5'-(n-substitutees)

Publications (1)

Publication Number Publication Date
CA2392369A1 true CA2392369A1 (fr) 2001-05-31

Family

ID=22605594

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002392369A Abandoned CA2392369A1 (fr) 1999-11-23 2000-11-16 Traitement des troubles du rythme cardiaque au moyen de carboxamidoadenosines n6-substitutees-5'-(n-substitutees)

Country Status (12)

Country Link
EP (1) EP1239864A1 (fr)
JP (1) JP2003514863A (fr)
KR (1) KR20020069188A (fr)
AU (1) AU782715B2 (fr)
CA (1) CA2392369A1 (fr)
IL (1) IL149470A0 (fr)
MX (1) MXPA02005088A (fr)
MY (1) MY135962A (fr)
NO (1) NO20022393L (fr)
NZ (1) NZ518861A (fr)
TW (1) TWI257306B (fr)
WO (1) WO2001037845A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004238217A1 (en) * 2003-04-24 2004-11-25 Aderis Pharmaceuticals, Inc. Method of treating atrial fibrillation or atrial flutter
WO2005025545A2 (fr) * 2003-09-17 2005-03-24 Aderis Pharmaceuticals, Inc. Formulation a liberation controlee
ATE541927T1 (de) 2004-04-02 2012-02-15 Japan Science & Tech Agency Kardioinhibitorisches/antihypertonisches neues endogenes physiologisch aktives peptid
EP1883646A1 (fr) 2005-05-19 2008-02-06 Cv Therapeutics, Inc. Agonistes du recepteur de l'adenosine a1
PL2234614T3 (pl) 2007-12-21 2013-03-29 Aop Orphan Pharmaceuticals Ag Kompozycja farmaceutyczna do pozajelitowego podawania ultrakrótko działającego antagonisty receptora beta-adrenergicznego

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5310731A (en) * 1984-06-28 1994-05-10 Whitby Research, Inc. N-6 substituted-5'-(N-substitutedcarboxamido)adenosines as cardiac vasodilators and antihypertensive agents
EP0169009A3 (fr) * 1984-07-17 1988-08-31 FISONS plc Dérivés de dihydropyridine et leur préparation, leur formulation et leur utilisation comme produits pharmaceutiques
US4738954A (en) * 1985-11-06 1988-04-19 Warner-Lambert Company Novel N6 -substituted-5'-oxidized adenosine analogs

Also Published As

Publication number Publication date
EP1239864A1 (fr) 2002-09-18
IL149470A0 (en) 2002-11-10
NO20022393D0 (no) 2002-05-21
JP2003514863A (ja) 2003-04-22
NO20022393L (no) 2002-06-24
WO2001037845A1 (fr) 2001-05-31
AU1613201A (en) 2001-06-04
NZ518861A (en) 2004-11-26
TWI257306B (en) 2006-07-01
MY135962A (en) 2008-07-31
AU782715B2 (en) 2005-08-25
MXPA02005088A (es) 2004-08-23
KR20020069188A (ko) 2002-08-29

Similar Documents

Publication Publication Date Title
Faro et al. Myocardial protection by PJ34, a novel potent poly (ADP-ribose) synthetase inhibitor
EP1110554B1 (fr) Compositions medicinales pour le traitement des maladies oculaires
DK2424546T3 (en) PROCESS FOR REDUCING intraocular pressure IN PEOPLE
WO1990009163A2 (fr) Procede et composes de liberation d'aica-riboside et de reduction du taux de glucose dans le sang
US20020147174A1 (en) Adenosine cyclic ketals: novel adenosine analogues for pharmacotherapy
PT99690B (pt) Metodo para o tratamento de doencas utilizando derivados de 2'-o-alquil-adenosina e para a preparacao de composicoes que os contem e de um hidrato de 6-ciclo- -hexil-2'-ometil-adenosina
Wiedmeier et al. Effects of catecholamines, histamine, and nitroglycerin on flow, oxygen utilization, and adenosine production in the perfused guinea pig heart.
MX2012010723A (es) Compuestos de adenosina y uso de los mismos.
AU782715B2 (en) Treatment of heart rhythm disturbances with N6-substituted-5'-(N-substituted) carboxamidoadenosines
US6784165B1 (en) Treatment of heart rhythm disturbances with N6-substituted-5′-(N-substituted) carboxamidoadenosines
EP3906969A1 (fr) Composé polyol antihypertenseur et dérivé de celui-ci
US7074773B2 (en) Pharmaceutical composition for diabetic neuropathy
EP1633371A1 (fr) Methode de traitement de la fibrillation auriculaire ou du flutter auriculaire
EP1315508B1 (fr) Utilisation de purine ribosides comme antiarythmiques
AU2001292591A1 (en) Purine ribosides as antiarrhythmics
JP3881174B2 (ja) 眼疾患治療用医薬組成物
JP2774169B2 (ja) 心臓または脳の虚血性疾患の治療・予防剤
RU2248208C2 (ru) Пуринрибозиды в качестве антиаритмических средств
Frishman et al. Antiarrhythmic Agents
JPWO2000012098A1 (ja) 眼疾患治療用医薬組成物
Schneeweiss et al. Bipyridine Derivatives
WO2007053415A2 (fr) Agents pour le traitement d’arythmies cardiaques

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued